Immunotherapy Coverage from Every Angle
Advertisement
Advertisement

Ongoing CE Activities

Tumor Mutational Burden, Neoantigens, and a Pathway to Predicting Response to Checkpoint Inhibitors
Immunotherapy for cSCC: How, Why, and When (login required)
Cases From the Community: Clinical Investigators Provide Their Perspectives on the Use of Immune Checkpoint Inhibitors in the Management of Actual Patients With Genitourinary Cancers
The Emerging Role of Immunotherapy in Head and Neck Cancers: An Integrated Approach (login required)
JADPRO Regional Lectures: Immunotherapy: Head & Neck Case Studies
Expanding Treatment Options in SCCHN: What Role Do Cancer Immunotherapies Have? (login required)
JADPRO Regional Lectures: Clinical Management of Novel Therapies for Hematologic Malignancies: Targeted Therapies, CAR-T, and Beyond
Immuno-Oncology Therapy Essentials: Proactive Management of Immune-Related Adverse Events
Minimizing the Impact of imAEs and Maximizing Efficacy: Pulmonary Toxicity
Immune Checkpoint Inhibitors in Lung Cancer: No Longer the Road Less Traveled?
Stage III NSCLC: Practical Application of Immune Checkpoint Inhibition After Chemoradiotherapy
Management of Advanced NSCLC: Where Do Immune Checkpoint Inhibitors Fit In?:
JADPRO Regional Lectures: Immunotherapy: Case Studies in Non-Small Cell Lung Cancer
Integration of Immunotherapies Into the Treatment of Patients With Non–Small Cell Lung Cancer
Immunotherapy in Advanced NSCLC: Will Combination Therapies Become Standard?
NCCN Pharmacy Updates: The Evolving Landscape of Immunotherapy and Targeted Therapy for Non–Small Cell Lung Cancer
Checkpoint Inhibitors in First-Line Advanced NSCLC: What Should You Know?
Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care-Lung Cancer: Advanced Disease
Cases from the Community: Clinical Investigators Provide Their Perspectives on the Use of Immune Checkpoint Inhibitors in the Management of Actual Patients with Genitourinary Cancers
JADPRO Regional Lectures: Immunotherapy: Renal Cell & Urothelial
Expert Guidance for Optimizing Immune Checkpoint Inhibitor Therapy for Kidney and Bladder Cancer
Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition (login required)
Advanced Renal Cell Carcinoma: combination, sequential strategies, & immunotherapy
JADPRO Regional Lectures: Clinical Management of Novel Therapies for Hematologic Malignancies: Targeted Therapies, CAR-T, and Beyond
High-Rick Relapsing MM: Retreatment With Immunomodulatory Therapy
Copyright © 2019 National Comprehensive Cancer Network, All Rights Reserved
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.